BRIEF published on 11/04/2024 at 11:51, 5 months 3 days ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 5 months 3 days ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 5 months 3 days ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 5 months 3 days ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 5 months 27 days ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 5 months 27 days ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 5 months 27 days ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 5 months 27 days ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 8 months 29 days ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 8 months 29 days ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 04/08/2025 at 04:00, 2 hours 54 minutes ago Leapmotor Selects QNX to Power New Electric SUV, the B10
Published on 04/07/2025 at 23:30, 7 hours 24 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 04/07/2025 at 23:30, 7 hours 24 minutes ago Electric Metals Announces Private Placement Offering
Published on 04/07/2025 at 22:05, 8 hours 49 minutes ago Vox Royalty Reports Major Financing Development at the Bullabulling Gold Project and Provides Western Australian Gold Sector Update
Published on 04/07/2025 at 22:05, 8 hours 49 minutes ago Second Tranche Closing of US$4 Million Private Placement
Published on 04/08/2025 at 06:45, 8 minutes ago Change in Group Management: Bernhard Mächler to succeed Group CFO Andreas Fecker
Published on 04/08/2025 at 06:30, 24 minutes ago ASMALLWORLD Honoured With Regional Virtuoso Award For Top Producing Cruise Member In Continental Europe
Published on 04/07/2025 at 22:20, 8 hours 33 minutes ago EQS-Adhoc: Infineon Technologies AG: Infineon Technologies AG enters agreement to buy Marvell Technology’s Automotive Ethernet business
Published on 04/07/2025 at 22:10, 8 hours 44 minutes ago Amrize Completes $3.4 Billion Bond Offering Ahead of Planned Spin-Off
Published on 04/07/2025 at 19:00, 11 hours 54 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 31 MARS 2025 au 04 AVRIL 2025
Published on 04/07/2025 at 19:00, 11 hours 54 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/07/2025 at 19:00, 11 hours 54 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES MARS 2025
Published on 04/07/2025 at 19:00, 11 hours 54 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/07/2025 at 19:00, 11 hours 54 minutes ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES MARS 2025
Published on 04/07/2025 at 18:00, 12 hours 54 minutes ago SMTPC - Communiqué sur la mise à disposition du Rapport annuel 2024
